{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:45:20Z","timestamp":1789202720876,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1996,1,1]],"date-time":"1996-01-01T00:00:00Z","timestamp":820454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1996,1,1]],"date-time":"1996-01-01T00:00:00Z","timestamp":820454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[1996,1]]},"DOI":"10.1023\/a:1016004611847","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T20:59:24Z","timestamp":1041109164000},"page":"10-11","source":"Crossref","is-referenced-by-count":14,"title":["How Much Compliance Is Enough?"],"prefix":"10.1007","volume":"13","author":[{"given":"John","family":"Urquhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"306496_CR1","first-page":"617","volume":"307","author":"J. Guillebaud","year":"1993","unstructured":"Guillebaud J. Any questions? Brit Med J 307: 617 (1993).","journal-title":"Brit Med J"},{"key":"306496_CR2","unstructured":"ORTHO-NOVUM Tablets. Physicians' Desk Reference. Oradell (NJ): (1995) pp 1795\u20131804."},{"key":"306496_CR3","first-page":"195","volume-title":"Compliance in Medical Practice and Clinical Trials","author":"LS. Potter","year":"1991","unstructured":"Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Compliance in Medical Practice and Clinical Trials. Ed: Cramer JA, Spilker B. New York: Raven Press, (1991) pp 195\u2013207."},{"key":"306496_CR4","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/0010-7824(94)90113-9","volume":"50","author":"MF McCann","year":"1994","unstructured":"McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 50 (suppl 1), S9\u2013S195 (1994).","journal-title":"Contraception"},{"key":"306496_CR5","unstructured":"NORPLANT System. Physicians' Desk Reference, 49th ed. Oradell (NJ): Medical Economics, (1995) pp 2696\u20132700."},{"key":"306496_CR6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00045391-199412000-00003","volume":"1","author":"BF Johnson","year":"1994","unstructured":"Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther 1: 260\u20137 (1994).","journal-title":"Am J Ther"},{"key":"306496_CR7","first-page":"301","volume-title":"Compliance in Medical Practice and Clinical Trials","author":"J. Urquhart","year":"1991","unstructured":"Urquhart J. Patient compliance as an explanatory variable in four selected cardiovascular studies. In: Compliance in Medical Practice and Clinical Trials. Eds: Cramer JA, Spilker B. New York: Raven Press, (1991) pp 301\u201322."},{"key":"306496_CR8","first-page":"1","volume-title":"Controlled-Release Pharmaceuticals","author":"J. Urquhart","year":"1981","unstructured":"Urquhart, J. Performance requirements for controlled-release dosage forms: therapeutic and pharmacological perspectives. In: Urquhart J, Ed. Controlled-Release Pharmaceuticals. Washington: American Pharmaceutical Association, (1981) pp 1\u201348."},{"key":"306496_CR9","first-page":"13","volume":"73","author":"PA Meredith","year":"1994","unstructured":"Meredith PA, Elliott HL. Therapeutic coverage: reducing the risks of partial compliance. Brit J Clin Pract Suppl 73, 13\u201317 (1994).","journal-title":"Brit J Clin Pract Suppl"},{"key":"306496_CR10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/clpt.1993.145","volume":"54","author":"G. Levy","year":"1993","unstructured":"Levy G. A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther 54: 252\u20134 (1993).","journal-title":"Clin Pharmacol Ther"},{"key":"306496_CR11","unstructured":"Anon. Helping patients to make the best use of medicines. Drug Therap Bull 39, no 1, Jan 7, 1991."},{"key":"306496_CR12","first-page":"213","volume":"245","author":"T Pullar","year":"1990","unstructured":"Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? Pharm J 245: 213\u20135 (1990).","journal-title":"Pharm J"},{"key":"306496_CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00280102","volume":"41","author":"R. Vander Stichele","year":"1991","unstructured":"Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 41: 27\u201335 (1991).","journal-title":"Eur J Clin Pharmacol"},{"key":"306496_CR14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00227361","volume":"70","author":"W. Kruse","year":"1992","unstructured":"Kruse W. Patient compliance with drug treatment-new perspectives on an old problem. Clin Invest 70:163\u20136 (1992).","journal-title":"Clin Invest"},{"key":"306496_CR15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2165\/00003088-199427030-00004","volume":"27","author":"J. Urquhart","year":"1994","unstructured":"Urquhart J. Role of patient compliance in clinical pharmacokinetics: review of recent research. Clin Pharmacokinet 27: 202\u201315 (1994).","journal-title":"Clin Pharmacokinet"},{"key":"306496_CR16","first-page":"453","volume":"32","author":"W Kruse","year":"1994","unstructured":"Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 32: 453\u20137 (1994).","journal-title":"Int J Clin Pharmacol Ther"},{"key":"306496_CR17","unstructured":"Anon. Long-term use of beta blockers: the need for sustained compliance. WHO Drug Information 4: 52\u20133 (1990)."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1016004611847.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1016004611847\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1016004611847.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T06:41:00Z","timestamp":1754030460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1016004611847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1996,1]]}},"alternative-id":["306496"],"URL":"https:\/\/doi.org\/10.1023\/a:1016004611847","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,1]]}}}